Visa reports July 28, 2026 at 5pm ET. EPS consensus: $3.23 (+8.4% YoY), revenue consensus ~$11.35B (+11.6%). Visa beat EPS consensus in at least eight of the last ten quarters on strong global payment volumes. No Polymarket/Kalshi contract found; probability based on historical beat rate (~85%).
Apple reports July 30, 2026 at 5pm ET. EPS consensus: $1.89 (+19.8% YoY), revenue consensus $108.9–110B. Apple beat EPS consensus in each of the last four quarters. Zacks Earnings ESP +0.53% (bullish); Goldman Sachs expects both EPS and revenue beat. No Polymarket contract found.
A Reuters poll shows 40 of 41 economists expect the SNB to hold at 0.00% on September 25, 2026 (1 expects a cut to -0.25%). SNB Chairman Schlegel explicitly cited 'undesirable side effects' of negative rates. Swiss inflation is on target, the franc is stable. Note: The actual SNB meeting is September 25 — not September 18 as erroneously listed in a parallel open forecast.
Coca-Cola has beaten EPS consensus in ~80% of the last eight quarters. Q2-2026 consensus is approx. $0.92 Non-GAAP EPS (+5.6% YoY, source: Yahoo Finance Earnings Preview 21 July 2026). KO benefits from strong pricing power in emerging markets, international volume growth, and a diversified portfolio. No Polymarket/Kalshi market found. Estimate of 73% = ~80% historical beat rate discounted for tariff and commodity risks.
Microsoft reports Q4 FY2026 results (~July 29, April–June 2026 quarter, fiscal year end June 30). Non-GAAP EPS consensus is approximately USD 3.50. Microsoft has beaten EPS consensus for at least 18 consecutive quarters. Azure Cloud continues to grow >35% YoY driven by AI workloads (OpenAI partnership, Copilot). Analog: Alphabet beat its consensus by 216% on July 22, 2026 (EPS $9.11 vs. $2.89 consensus), primarily via Google Cloud (+82%) and Anthropic stake. A similar AI-infrastructure tailwind supports Microsoft's Azure. No Polymarket contract identified for this specific event.
fxleaders.com reported July 24, 2026: 'September Hike Odds Jump to 80%' — triggered by Brent ~$100, rising US Treasury yields, elevated inflation expectations. Polymarket already shows 25% chance of July hike; if July holds (74–81%), September pressure rises sharply. Fed Chair Kevin Warsh is seen as inflation-sensitive hawk; Jackson Hole (Aug 27–29) will likely serve as signaling platform (see open prediction). Market-implied September hike probability: ~75–80% — applied here with slight discount: 73%.
Meta reports after market close July 29, 2026. Analyst Non-GAAP EPS consensus ~$7.23 (AlphaStreet/MarketBeat, July 2026). In Q1 2026, Meta beat $5.47 consensus with $6.43. Key drivers: AI-powered advertising (Advantage+), Reels monetization, Instagram growth. Main risk: $125–145B capex guidance for 2026 may overshadow EPS beat. Meta beat in ≥6 of last 8 quarters. No direct Polymarket odds; historical beat rate supports ~70%.
Nina Kennedy (AUS) is the Paris 2024 Olympic champion and Australia's flag bearer at Glasgow 2026. She is pursuing her publicly announced 'Project Five Metres'. Kennedy is the clear favourite with no comparable rival in the Commonwealth field. No market quotes; assessment based on world rankings and title pedigree.
Diageo (Johnnie Walker, Guinness, Smirnoff, Baileys) cut its organic revenue outlook to minus 2 to minus 3% for the full year in the Q3 FY2026 trading update (May 2026). North America posted a high-single-digit organic decline in Q3. FY2025 had still shown +1.7% organic growth — the deterioration is sharp. Drivers: GLP-1 drug headwind on alcohol consumption, US destocking, and weak Shui Jing Fang segment in China. No market quotes available; forecast anchored directly on company guidance.
AMD has beaten adjusted EPS consensus for eight consecutive quarters. The new Instinct MI450 AI GPU accelerators and Helios rack-scale AI system were unveiled at AMD Advancing AI 2026 (San Francisco, July 2026). The data centre segment benefits massively from the ongoing AI infrastructure boom. Consensus EPS approx. USD 1.60 (Barchart, July 2026). No Polymarket/Kalshi quotes for AMD Q2 2026 available; calibrated on the eight-quarter beat rate.
Tatjana Smith (RSA) is the dominant force in Commonwealth breaststroke: African record in 100m (1:04.13, 2024), world champion, and the only athlete in the field with consistent sub-1:05 times. Closest rival Kaylene Corbett (RSA, ~1:06.x) is well behind. Ariarne Titmus (AUS), the strongest Australian swimmer, retired from competitive sport and is working as a Seven News reporter at the Games – Australia's breaststroke dominance is absent. Bookmaker odds not aggregated for CWG swimming; based on 2025/26 world rankings, Smith leads the Commonwealth field by a wide margin.
The FTSE 100 stood at 10,702 points on 24 July 2026 (+0.59%, source: BBN Times / Sunday Guardian Live). The 10,500 threshold is 1.9% below the daily close. Supporting factors: Brent crude at $97–100/barrel (supports UK energy stocks BP, Shell), UK Retail Sales June 2026 +1.0% MoM (solid domestic demand), BoE meeting July 30 (hold at 3.75% expected, open prediction). Risks: US earnings shocks in week 31 (Meta, Microsoft, Apple, Amazon), Middle East geopolitics. Historical FTSE 100 volatility ~12% p.a. implies a >1.9% downside probability in 7 days of ~16–18%. No Polymarket market available for FTSE 100. Prediction: 81% probability of close above 10,500.
The PDUFA date for iberdomide (combination with daratumumab + dexamethasone, EXCALIBER-RRMM Phase 3 study) is August 17, 2026. BMS received both Breakthrough Therapy and Priority Review designation – both signals of strong regulatory support. The FDA historically approves ~83–87% of applications reaching a PDUFA date; with Breakthrough Therapy designation the rate is even higher (>90%). No negative Advisory Committee signal is known. Cassandra estimates the approval probability at 78% (slight discount vs historical average for a complex combination therapy).